Tags : QUAZAR AML-001

Celgene Reports Results of CC-486 in P-III QUAZAR AML-001 Study

Shots: The P-III QUAZAR AML-001 study involves assessing of CC-486 (300mg) as maintenance therapy vs PBO + SoC in 472 patients in a ratio (1:1) with AML who achieved first CR with incomplete blood count recovery (CRi) with induction chemotherapy (with/out consolidation) The P-III QUAZAR AML-001 study resulted in meeting its 1EPs & 2EPs i.e, […]Read More